Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monica Bubenik

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Bioorganic & Medicinal Chemistry Letters|February 5, 2003
Thiophene-based vitronectin receptor antagonistsMonica Bubenik, Karen Meerovitch, Frédéric Bergeron, et al.
Bioorganic & Medicinal Chemistry Letters|October 10, 2002
Novel nucleotide phosphonate analogues with potent antitumor activityMonica Bubenik, Rabindra Rej, Nghe Nguyen-Ba, et al.
Vascular Pharmacology|March 21, 2003
A novel RGD antagonist that targets both alphavbeta3 and alpha5beta1 induces apoptosis of angiogenic endothelial cells on type I collagenKaren Meerovitch, Frédéric Bergeron, Lorraine Leblond, et al.
Bioorganic & Medicinal Chemistry Letters|December 14, 2007
Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based HTS assay. Part 5: modifications of the 2- and 3-positionsWilliam Kemnitzer, Songchun Jiang, Yan Wang, et al.
ACS Medicinal Chemistry Letters|February 18, 2026
Design of a Targeted Covalent Probe to Interrogate the DNA Polymerase Activity of PolθMonica Bubenik, Pavel Mader, Stephen Orlicky, et al.
Bioorganic & Medicinal Chemistry Letters|January 12, 2015
Synthesis and evaluation of NS5A inhibitors containing diverse heteroaromatic coresJames A Henderson, Darius Bilimoria, Monica Bubenik, et al.
Bioorganic & Medicinal Chemistry Letters|January 12, 2015
Benzimidazole-containing HCV NS5A inhibitors: effect of 4-substituted pyrrolidines in balancing genotype 1a and 1b potencyJames A Henderson, Darius Bilimoria, Monica Bubenik, et al.
Journal of Medicinal Chemistry|May 16, 2025
Discovery of RP-1664: A First-in-Class Orally Bioavailable, Selective PLK4 InhibitorFrédéric Vallée, Matias Casás-Selves, Monica Bubenik, et al.
Journal of Medicinal Chemistry|September 20, 2022
Identification of <b>RP-6685</b>, an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of PolθMonica Bubenik, Pavel Mader, Philippe Mochirian, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Bioorganic & Medicinal Chemistry Letters|February 5, 2003
Thiophene-based vitronectin receptor antagonistsMonica Bubenik, Karen Meerovitch, Frédéric Bergeron, et al.
Bioorganic & Medicinal Chemistry Letters|October 10, 2002
Novel nucleotide phosphonate analogues with potent antitumor activityMonica Bubenik, Rabindra Rej, Nghe Nguyen-Ba, et al.
Vascular Pharmacology|March 21, 2003
A novel RGD antagonist that targets both alphavbeta3 and alpha5beta1 induces apoptosis of angiogenic endothelial cells on type I collagenKaren Meerovitch, Frédéric Bergeron, Lorraine Leblond, et al.
Bioorganic & Medicinal Chemistry Letters|December 14, 2007
Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based HTS assay. Part 5: modifications of the 2- and 3-positionsWilliam Kemnitzer, Songchun Jiang, Yan Wang, et al.
ACS Medicinal Chemistry Letters|February 18, 2026
Design of a Targeted Covalent Probe to Interrogate the DNA Polymerase Activity of PolθMonica Bubenik, Pavel Mader, Stephen Orlicky, et al.
Bioorganic & Medicinal Chemistry Letters|January 12, 2015
Synthesis and evaluation of NS5A inhibitors containing diverse heteroaromatic coresJames A Henderson, Darius Bilimoria, Monica Bubenik, et al.
Bioorganic & Medicinal Chemistry Letters|January 12, 2015
Benzimidazole-containing HCV NS5A inhibitors: effect of 4-substituted pyrrolidines in balancing genotype 1a and 1b potencyJames A Henderson, Darius Bilimoria, Monica Bubenik, et al.
Journal of Medicinal Chemistry|May 16, 2025
Discovery of RP-1664: A First-in-Class Orally Bioavailable, Selective PLK4 InhibitorFrédéric Vallée, Matias Casás-Selves, Monica Bubenik, et al.
Journal of Medicinal Chemistry|September 20, 2022
Identification of <b>RP-6685</b>, an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of PolθMonica Bubenik, Pavel Mader, Philippe Mochirian, et al.
Pageof 1